Biopure Case Summary

Comparing these potential market size, we can easily observe that Oxyglobin is roughly two times as profitable as Hemopure. Accordingly, Biopure should take these data into account to evaluate whether or not to launch Oxyglobin immediately. On the other hand, this revenue expectation is not so realistic. In fact, it is almost impossible that the company will capture the whole potential markets because of its small production capacity. This latter represents the main obstacle to a potential success of Biopure in both animal and human

Biometra is a small company based in the Boston suburb of Woburn which was recently acquired by Scientific Materials (SciMat), in order to deepen its portfolio in vascular medical devices. Biometra focused chiefly on catheters, or tubes used to drain or inject fluids or to allow access of surgical instruments for medical procedures. The catheter would be the first product ever launched by Biometra and so its success was critical for both the companies.

Those target markets who rely on Johnson & Johnson health and medical needs are mostly patients, doctors, nurses and civilians. Therefore, the company need to sustain their products and services over all these years to ensure that lower income people and underprivileged patients are able to access on their medicines. This however requires the company to balance patient’s access and competitive dynamics in line with their need as the company need to have enough resources to keep on being innovating, creating new and better medicines and at the same time making sure there will be a fair return to the shareholder as well. Johnson & Johnson also work closely with the governments, physicians, non-government organizations and the international donors all around the world to provide its products within an affordable prices to its

Faboil Ltd has evolved into a relatively successful organisation in the biotechnology field. The success of the company and its paternal approach was adopted by Dr Alfred Brownlow. Dr Brownlow has led from the front in terms of developing the product range for Faboil Ltd. Richard Cranberry (Director of Biotechnology) has driven very hard to maintain the success of the company, although the organisation lag behind in terms of modus operandi technology. At present, the monopoly position of Faboil Ltd has slowly eroded away and faces two competitors. The major causes are that the new products have failed to live up to market expectations and it is at a backward stage only holding a 20% market share. This report will find the

Plasma is used to keep a healthy blood pressure, supplying proteins for blood clotting and immunity, and serves as the medium for the exchange of vital minerals. It is attained by separating the liquid part of the blood from the cells. Dr. Charles Drew set up a blood plasma system in 1938; he set up a blood bank at Columbia Medical Center by 1939. Drew then discovered that plasma could replace whole blood; this discovery played a huge role during the war in places with severe atrocities. Blood was in high demand in 1940 as war raged across Europe. The International Transfusion Association chose Dr. Drew to organize the Blood for Britain project. This project collected, processed, and transported 14,500 units of plasma within five months. The research of Dr. Drew transformed plasma transfusion so plasma could be given on the battlefield immediately. Dr. Drew was appointed Director of the first American Red Cross Blood Bank in February 1941. This plasma collection and preservation program is a model for today’s blood donation organizations. When the program ended in September 1945, the American Red Cross had gathered over 13 million units of blood and transformed most of it into plasma. By the end of the war, 1.3 million plasma units were returned to the American Red Cross, which were given to civilian hospitals (World War

t all began in 1818 according to the Blood Centers of the Pacific the first recorded successful human blood transfusion was accomplished during this era. However due to the lack of knowledge and research, it was followed by many blood transfusion failures. But 80 years later, scientists discovered that our red blood cells are different from one another, which was the cause of many incompatibilities blood transfusions in the 1800's. Due to this four blood types were identified - A, B, AB and O. This discovery revolutionized hematology and led the way for successful blood transfusions.

The United States Department of Health and Human Services has a pattern blood donation policies that is important to consider when evaluating their current policies. In the 1980s there was a lifetime ban on Haitians donating blood. There are notable parallels between the current MSM policy and the Haitian policy of the 80s. First, the high risk grouping was based on identity rather than behaviors. The policies were both based on assumption of high risk and stereotyping based on sexuality or race. Another shortcoming of the CDC has been the lack of representation of individuals who will be impacted by the policies. In both cases, Haitians and MSM have not been included in governing bodies that make these decisions. Finally, both policies

Additionally, “Adrenaclick, a significantly cheaper alternative… is rarely recommended by major medical societies, as its two caps that must be removed (contrasted to EpiPen’s one) are viewed as inconvenient” (Emanuel 2). When competitors are unable to produce goods or services of equivalent quality, Mylans product becomes unique instead of homogenous. Furthermore, when a firm becomes the only producer of a good or service in an industry, this is referred to as a monopoly. “A monopoly is a firm with market power”, and “market power is the power to raise price above marginal cost without fear that other firms will enter the market”, (Cowen 236). This lack of competition allows Mylan to reap monopoly profits in the short and long run. Graph ‘A’ displays what happens when Mylan has no competition in the epinephrine industry. To maximize profit, Mylan would “produce until marginal revenue equals marginal cost”, (Cowen 236). This point occurs at the blue circle. Moving down from this point, one reaches the profit maximizing quantity at the x-axis intersection. This point is around 4,333,000. The quantity of EpiPens sold by Mylan per year was obtained by dividing the revenue stated in, “Mylan

In 1998, Biopure Corporation is one of the three legitimate contenders in the emerging field of “blood substitutes”. Biopure has invested $200M on the R&D on blood substitutes in the past with its primary goal being the development of a human blood substitute ( Hemopure) but Its entry into animal market (Oxyglobin) had been some

A balanced scorecard has four perspectives, Customer perspective, internal business perspective, Innovation and learning perspective, and financial perspectives. By using balanced scorecards, BIOCO knows what the customers needed is. It helps BIOCO to fulfill customers’ need better. For internal business perspective part, BIOCO can clear the corporate vision and strategy. BIOCO can adjust the strategy according to the pervious balanced scorecards. Also the balanced scorecards link everyone in the company and enhance the communications between each other. Meanwhile, Scorecards detailed the company’s business goals to everyone and guide every

Investigating haemoglobin (Hb) concentration in blood samples using the haemoglobincyanide method and in foetal haemoglobin samples

Despite the fact that Baxter International launched the first human blood substitute, HemAssist (presumably priced between $600 and $800), Baxter International’s and Northfield Laboratories’ blood substitutes rely on outdated human blood as a source of hemoglobin which is more

The possibility of incompatible donors and receivers is a looming beast which not only wastes a good organ, but can also harm the receiver. “Sometimes in living donation, the blood groups of the donor (person who is giving the organ) and recipient (person who is receiving the organ) don't match. In the past, up to 30% of all potential living donor transplants were considered impossible due to blood group and antibody incompatibilities. Recently however, it has become possible to transplant patients in this situation using specialised techniques. Only a few centres routinely perform this in the UK.” (Guys and St. Thomas Hospital, 2017) While we may want to fool ourselves into thinking that the “matchmaker” and other organ distributors are using these methods. They are not. They are only using the cheapest and easiest methods so they can have wider profit margins on their untaxed

In 1998, Biopure Corporation is one of the three legitimate contenders in the emerging field of “blood substitutes” along with Baxter International and Northfield

Bayer AG is fully committed to expanding its business operations through pharmaceuticals, consumer health, and crop science. Bayer AG understands that in order for the company to successfully expand its Pharmaceuticals department they must properly invest in research, development, and marketing of innovative medicinal products. In addition, Bayer AG is developing clinical programs, which will enable the company to provide various of its products to a greater number of people. Bayer AG ability to identify areas in medicine that remain untapped is crucial to the firm’s long term sustainability. For example, Bayer AG has identified the fields of cardiology, oncology, gynecology, and